ON THE ISSUE OF DAMAGE TO THE CIRCULATORY SYSTEM AND KIDNEYS IN COVID-19

Objective is to analyze the features of the influence of a new coronavirus infection (COVID-19) on the cardiovascular system and kidneys (in their relationship) based on the materials of domestic and foreign literature.Material and methods. The study of available literature data was carried out, clinical, laboratory and functional characteristicsof damage to the cardiovascular system and kidneys in patients with coronavirus infection caused by SARS-CoV-2 were determined.Summary. The severe course of the new coronavirus infection (COVID-19) can contribute to damage to the cardiovascular system, including the development of pulmonary embolism, myocardial infarction, myocarditis, pericarditis; cases of acute kidney injury (AKI) have been described. Attempts have been made to stratify the risk of cardiovascular complications caused by COVID-19; however, there is some inconsistency in the literature regarding the possibility of using cardiac troponins, creatine phosphokinase, and the N-terminal fragment of the pro-B-type natriuretic peptide as predictors of their development. Further study of such biomarkers as D-dimer, anticardiac antibodies, homocysteine, cystatin C, lipocalin 2, etc. in order to assess their role in predicting cardiovascular complications and AKI is an important and promising direction in therapy, cardiology and nephrology.In addition, most authors do not consider the identified disorders from the point of view of the functional proximity of the circulatory system and the kidneys. In this regard, it seems relevant to conduct a comprehensive study in order to form a holistic view of the pathogenesis and clinical picture of COVID-induced cardiorenal syndrome.

COVID-19, cardiorenal syndrome, troponins, CPK-MB, NT-pro-BNP, NGAL, D-dimer

1. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID19)», версия 15 (22.02.2022) [Электронный ресурс]. - URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/ 000/059/392/ original/%D0%92%D0%9C%D0%A0_COVID-19_V15.pdf (дата обращения: 15.05.2022)

2. COVID-19 Map [Электронный ресурс]. - URL: https://coronavirus.jhu.edu/map.html (дата обращения: 15.05.2022)

3. Новая коронавирусная болезнь (COVID-19) и сердечно-сосудистые заболевания / О.Л. Барбараш [и др.] // Комплексные проблемы сердечно-сосудистых заболеваний. - 2020. - Т. 9, № 2. - С. 17-28

4. Поражение сердечно-сосудистой системы при COVID-19 / А.В. Кравцива [и др.] // Вестник Смоленской государственной медицинской академии. - 2021. - Т. 20, № 4. - С. 59-65. doi:10.37903/vsgma.2021.4.8

5. Структурно-функциональные особенности острого повреждения миокарда при поражении новой коронавирусной инфекцией / Д.А. Килин [и др.] // Медицинский вестник Башкортостана. - 2021. - Т. 16, № 3(93). - С. 80-85

6. Анализ госпитальной смертности от COVID-19 среди жителей Кабардино-Балкарской республики / З.А. Ахкубекова [и др.] // Трудный пациент. - 2021. - Т. 19, № 6. - С. 18-21. doi:10.224412/2074-1005-2021-6-18-21

7. Armentano, G.M. Effect of COVID-19 on cardiorenal axis: known or unknown universe? / G.M. Armentano, M.S Carneiro-Ramos // Braz J Med Biol Res. - 2022. - Vol. 55, e11932. doi:10.1590/1414-431X2022e11932

8. Abnormal apelin-ACE2 and SGLT2 signaling contribute to adverse cardiorenal injury in patients with COVID-19. X.T. Li [et al.].Int J Cardiol. - 2021. - Vol. 336. - P. 123-129. doi:10.1016/j.ijcard.2021.05.029

9. Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. A Lala [et al.]. J Am Coll Cardiol. - 2020. - Vol. 76, № 5. - P. 533-546. doi:10.1016/j.jacc.2020.06.007

10. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. F. Zhou [et al.]. Lancet. - 2020. - Vol. 395(10229). - P. 1054-1062. doi:10.1016/S0140-6736(20)30566-3

11. Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China. S. Shi [et al.]. JAMA Cardiol. - 2020. - Vol. 5(7). - P. 802-810. doi:10.1001/jamacardio.2020.0950

12. Клиническая характеристика пациентов с COVID-19, поступающих в отделение интенсивной терапии. Предикторы тяжелого течения / Т.В. Клыпа [и др.] // Клиническая практика. - 2020. - Т. 11, № 2. - С. 6-20. doi:10.17816/clinpract34182

13. The prognostic role of cardiac troponin in hospitalized COVID-19 patients. I.H. Tanboğa [et al.]. Atherosclerosis. - 2021. - Vol. 325. - P. 83-88. doi:10.1016/j.atherosclerosis.2021.04.006

14. Redefining Cardiac Biomarkers in Predicting Mortality of Inpatients With COVID-19. J.-J. Qin [et al.]. Hypertension. - 2020. - Vol. 76(4). - P. 1104-1112. doi:10.1161/HYPERTENSIONAHA.120.15528

15. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. C. Huang [et al.]. Lancet. - 2020. - Vol. 395(10223). - P. 497-506. doi:10.1016/S0140-6736(20)30183-5

16. Franks, C.E. Elevated Cardiac Troponin I Is Associated with Poor Outcomes in COVID-19 Patients at an Academic Medical Center in Midwestern USA. / C.E. Franks, M.G. Scott, C.W. Farnsworth // J Appl Lab Med. - 2020. - Vol. 5(5). - P. 1137-1139. doi:10.1093/jalm/jfaa092

17. Kim, C.W. COVID-19, cardiovascular diseases and cardiac troponins / C.W. Kim, W.S. Aronow. // Future Cardiol. - 2022. - Vol. 18(2). - P. 135-142. doi:10.2217/fca-2021-0054

18. Хавкина, Д.А. Лабораторные особенности поражения сердечно-сосудистой системы при COVID-19 и других острых респираторных вирусных инфекциях / Д.А. Хавкина, П.В. Чухляев, Т.А. Руженцова. // Академия медицины и спорта. - 2021. - Т. 2, № 3. - С.5-7. doi:10.15829/2712-7567-2021-32

19. Оценка уровня антикардиальных антител у больных с тяжелым и среднетяжелым течением COVID-19 (корреляции с клинической картиной и прогнозом) / О.В. Благова [и др.] // Российский кардиологический журнал. - 2020. - Т.25, № 11. - С. 85-97. doi:10.15829/1560-4071-2020-4054

20. Катастрофический антифосфолипидный синдром при COVID-19 / Ю.С. Полушин [и др.] // Вестник анестезиологии и реаниматологии. - 2021. - Т. 18, № 1. - С. 17-26. doi:10.21292/2078-5658-2021-18-1-17-26

21. Organ function biomarker abnormalities, associated factors and disease outcome among hospitalized patients with COVID-19. S. Araya [et al.]. Biomark Med. - 2022. - Vol. 16(6). - P. 417-426. doi:10.2217/bmm-2021-0681

22. Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patients. Z. Yang [et al.]. Aging (Albany NY). - 2020. - Vol. 12(7). - P. 6037-6048. doi:10.18632/aging.102999

23. Acute Kidney Injury in COVID-19 Patients: An Inner City Hospital Experience and Policy Implications. U. Zahid [et al.]. Am J Nephrol. - 2020. - Vol. 51(10). - P. 786-796. doi:10.1159/000511160

24. The Association of COVID-19 With Acute Kidney Injury Independent of Severity of Illness: A Multicenter Cohort Study. D.G. Moledina [et al.]. Am J Kidney Dis. - 2021. - Vol. 77(4). - P. 490-499. doi:10.1053/j.ajkd.2020.12.007

25. Acute kidney injury in patients with COVID-19: a retrospective cohort study from Switzerland. M. Diebold [et al.]. Swiss Med Wkly. - 2021. - Vol. 151, w20482. doi:10.4414/smw.2021.20482

26. Clinical Characteristics and Outcomes of Communityand Hospital-Acquired Acute Kidney Injury with COVID-19 in a US Inner City Hospital System. J. Pelayo [et al.]. Cardiorenal Med. - 2020. - Vol. 10(4). - P. 223-231. doi:10.1159/000509182

27. Urinary tubular biomarkers as predictors of death in critically ill patients with COVID-19. G. F. Bezerra [et al.]. Biomarkers in medicine. - 2022. - Vol. 16(9). - P. 681-692. doi:10.2217/bmm-2021-0631